C5 and autoimmune disease: Even more recently, a number of C5 inhibitors were developed, including ravulizumab, a monoclonal Ab with enhanced effect duration (8), and zilucoplan, a small molecule inhibitor of C5 (9), among others, which have revolutionized the treatment of several autoimmune disorders.